Navigation Links
Regeneron Pharmaceuticals Announces Proposed Offering of Convertible Senior Notes due 2016
Date:10/17/2011

tock issuable upon conversion of the notes, nor shall there be any offer, solicitation or sale of any securities, including any notes or any shares of the Company's common stock issuable upon conversion of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Regeneron Pharmaceuticals, Inc.Regeneron is a fully integrated biopharmaceutical company that discovers, develops, manufacturers, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, which is approved for the treatment of a rare inflammatory condition, Regeneron has completed Phase 3 clinical trials of rilonacept for a new indication and of product candidates EYLEA™ (aflibercept injection; VEGF Trap Eye) in diseases of the eye and ZALTRAP® (aflibercept) (VEGF Trap) in colorectal cancer.  EYLEA is currently under review with U.S. and European regulatory authorities.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis, pain, cholesterol reduction, allergic and immune conditions, and cancer.  

Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"), which include, among other things, those concerning whether or not the Company will offer the notes or consummate the proposed offering, the final terms of the notes and the proposed offering, prevailing market conditions, the anticipated principal amount of the notes and the anticipated use of the proceeds of the proposed offering.  The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of the Act.  Forward-looking statements may be ident
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
2. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
3. Regeneron Announces Presentation at the 29th Annual J.P. Morgan Healthcare Conference
4. Regeneron Announces Presentation at the 2010 Deutsche Bank BioFest
5. Regenerons Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
6. Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
7. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
8. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
9. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
10. Elevation Pharmaceuticals Presents Positive Phase 2a Results in COPD Patients at the European Respiratory Society Annual Congress
11. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... An analysis of patented university inventions licensed to ... path to commercialization. To open these roadblocks, the ... results during the discovery stage could lead to ... are frequently derived from discoveries made in university ... well known during clinical trials, which have a ...
(Date:8/20/2014)... , Aug. 20, 2014  Decision Resources Group finds that ... Russia , India and ... billion in 2013, roughly equal to the size of ... the BRIC market will experience much faster growth as a result ... population. Other key findings from Decision Resources Group,s coverage ...
(Date:8/20/2014)... in your ear could improve the health of your ... University of Leeds used a standard TENS machine like ... pulses to the tragus, the small raised flap at ... the ear canal. , The stimulation changed the influence ... the nervous signals that can drive failing hearts too ...
(Date:8/19/2014)... and Markets  has announced the addition of the "Cell and ... their offering. This report analyzes the worldwide markets ... following Product Segments: Media, Sera, and Reagents. The report ... , Japan , Europe , ... . Annual estimates and forecasts are provided for the period 2013 ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3'Tickling' your ear could be good for your heart 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2
... SAN DIEGO, Nov. 20 Veridiam (www.veridiam.com) won the ... the 2009 Workplace Excellence Awards. The awards are sponsored ... and recognize innovative and exceptional human resources practices. , ... than 129 employee-nominated companies, honored at the recent awards ...
... ... webinar, “Roller Compactions Process Optimization Using At-Line Particle Characterization”, will be presented on December ... demonstrated to map the design space and optimize a series of roller compaction runs ... ...
... Dr. Mate Hidvegi, inventor of Avemar fermented wheat germ extract, ... Biropharma Kft, discrediting the Hungarian company for making false and ... Dr. Hidvegi stated from his office in Budapest, Hungary: ... apply to AveULTRA, www.aveultra.com , is misleading. ...
Cached Biology Technology:Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category 2Roller Compaction Process Optimization Using At-Line Particle Characterization 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2
(Date:8/20/2014)... are athletes who have suffered concussions ready to return ... found that high school athletes who head back on ... a significant regression in their abilities to simultaneously walk ... seen in changes in their balance and/or altered walking ... of the 12 had returned to activity in less ...
(Date:8/20/2014)... one day be made out of cocoa, rice and ... The novel process they developed and their results, which ... plastic waste problems, appear in the ACS journal ... colleagues at the Italian Institute of Technology point out ... production reached 288 million tons worldwide, but its ubiquity ...
(Date:8/20/2014)... have developed methods for electronically manipulating the flight muscles ... use to control those muscles. The work opens the ... for use in emergency response. , "In the big ... the movement of moths for use in applications such ... an assistant professor of electrical and computer engineering at ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3Research paves way for development of cyborg moth 'biobots' 2
... Research Institute is reporting a discovery that sheds light ... the normal processes that govern the everyday life of ... diseases, including cancer and septic shock. , The discovery ... their relationship to the genetic transcripts known as messenger ...
... to fathom a proverb ?catch the figurative meaning of "an ... research led by V. S. Ramachandran, director of the Center ... Diego, a region of the brain known as the angular ... ability to understand metaphor. , Ramachandran and colleagues tested four ...
... by a team of researchers at Penn State, which also ... to control tissue growth. The team's genetic and biochemical studies ... the journal Cell. "This discovery extends our understanding of how ... the formation of tumors, and it raises the possibility that ...
Cached Biology News:Cooperation is key—a new way of looking at MicroRNA and how it controls gene expression 2Cooperation is key—a new way of looking at MicroRNA and how it controls gene expression 3Cooperation is key—a new way of looking at MicroRNA and how it controls gene expression 4Grasping metaphors: UC San Diego research ties brain area to figures of speech 2New tumor-suppressor gene discovered 2New tumor-suppressor gene discovered 3New tumor-suppressor gene discovered 4
... a group of enzymes involved in matrix ... metalloproteinase family ten exist in soluble form ... MT1-MMP, MT2-MMP, MT3-MMP also known as MMP14, ... domain anchoring them to the cell surface. ...
...
... IKATUBE ULTRA TURRAX Tube Disperser System from IKA ... It offers a cleaner, safer, and more efficient ... sample volumes from 2 to 15 ml inside ... can choose one of 4 different tube types. ...
...
Biology Products: